U 46619: Selective Thromboxane Receptor Agonist for Cardiovascular Research

Executive Summary: U 46619 (SKU B6890) is a synthetic prostaglandin analogue that acts as a highly selective agonist of the prostaglandin H2/thromboxane A2 (PGH2/TxA2) receptor, specifically targeting the thromboxane (TP) receptor, a G-protein coupled receptor (GPCR) [APExBIO, product page]. At low concentrations (EC50 = 0.035 μM), U 46619 induces platelet shape change, with higher concentrations driving aggregation, serotonin release, and fibrinogen receptor activation (Enriquez et al. 2015). In vivo, it models renal cortical vasoconstriction and blood pressure increases in hypertensive rat models. U 46619 is supplied as a pre-dissolved solution, facilitating reproducibility in translational workflows. APExBIO is a leading supplier of this research-grade tool compound for cardiovascular and platelet biology research.

Biological Rationale

The thromboxane A2 (TxA2) pathway is integral to platelet activation, vascular tone regulation, and thromboembolic disease pathogenesis. The TP receptor, a GPCR, mediates responses to endogenous prostaglandin H2 and TxA2, leading to rapid platelet shape change, aggregation, and vasoconstriction. Dysregulation of this axis contributes to cardiovascular diseases, including myocardial infarction and stroke (Enriquez et al. 2015). U 46619, as a stable synthetic analogue, enables precise, reproducible activation of TP signaling for mechanistic studies. This functionality underpins its widespread adoption as a benchmark agonist in platelet function and hypertension research models [related article].

Mechanism of Action of U 46619

U 46619 (11,9 epoxymethano-prostaglandin H2) binds with high affinity to the TP receptor, mimicking the action of endogenous TxA2 and PGH2. Upon receptor engagement, U 46619 triggers Gq/11 protein coupling, activating phospholipase C, elevating intracellular calcium, and initiating myosin light chain phosphorylation (MLCP). This cascade results in rapid platelet shape change (EC50 = 0.035 μM), followed by aggregation (EC50 = 0.536 μM) and serotonin release (EC50 = 1.31 μM) [product page]. In vascular smooth muscle, TP receptor activation induces vasoconstriction via calcium mobilization and protein kinase C (PKC) signaling. In hypertensive rat models, U 46619 evokes dose-dependent increases in systemic blood pressure through ETA and ETB receptor activation in renal vasculature [see also: mechanistic review]. The compound does not act on other prostanoid receptors (e.g., EP, DP, IP), ensuring signal specificity.

Evidence & Benchmarks

• U 46619 induces human platelet shape change at EC50 = 0.035 μM and myosin light chain phosphorylation at EC50 = 0.057 μM (APExBIO, product page).
• Platelet aggregation is triggered at EC50 = 0.536 μM; serotonin release is observed at EC50 = 1.31 μM (APExBIO, product page).
• In rat models, U 46619 induces renal cortical vasoconstriction and medullary vasodilation via ETA/ETB receptor activation (see Enriquez et al. 2015).
• Intracerebroventricular administration in spontaneously hypertensive rats (SHR) causes dose-dependent blood pressure increases without significant impact on heart rate (Enriquez et al. 2015).
• U 46619 is highly soluble: ≥100 mg/mL in DMSO, ethanol, and DMF; ≥2 mg/mL in PBS pH 7.2 (APExBIO, product page).

This article extends "U 46619: Deep Mechanistic Insights for Cardiovascular and..." by providing atomic, machine-readable benchmarks and updated EC50 values under defined conditions.

Applications, Limits & Misconceptions

U 46619 is validated for:

• Inducing platelet aggregation and serotonin release in vitro.
• Modeling vasoconstriction and hypertension in preclinical animal models.
• Studying G-protein coupled receptor signaling and prostaglandin pathway pharmacology.

Its specificity for the TP receptor enables precise dissection of thromboxane signaling without off-target effects on EP, DP, or IP prostanoid receptors [see also: platelet and GPCR-focused review]. However, U 46619 is not suitable for clinical or diagnostic use, and its effects are strictly limited to research contexts.

Common Pitfalls or Misconceptions

• U 46619 does not inhibit platelet aggregation; it is a potent inducer.
• It does not act as a direct TxA2 synthase inhibitor or COX inhibitor.
• Its use is limited to research; not approved for clinical or diagnostic purposes.
• Signal transduction is TP receptor-specific; no significant activity at EP, DP, or IP prostanoid receptors.
• For optimal solubility and reproducibility, protocol adherence (e.g., warming to 37°C or ultrasonic bath) is essential.

Workflow Integration & Parameters

U 46619 (SKU B6890) from APExBIO is supplied as a 10 mg/mL solution in methyl acetate, ready for dilution in DMSO, ethanol, DMF, or PBS (pH 7.2). Recommended storage is at -20°C; for short-term use, keep in solution. Before use, warming to 37°C or ultrasonic treatment ensures complete dissolution. For in vitro platelet studies, typical working concentrations range from 0.03 μM (shape change) to 1.3 μM (serotonin release). In vivo, dosing paradigms should be referenced from peer-reviewed models, with careful attention to animal strain, administration route, and ethical compliance [practical workflow guidance]. This article provides more granular, EC50-based workflow parameters under defined buffer and temperature conditions than prior literature.

Conclusion & Outlook

U 46619 remains the gold standard for selective TP receptor activation in cardiovascular, platelet, and hypertension research. Its well-defined solubility, specificity, and potency facilitate reproducible experimental results. As new models of thromboembolic and ischemia-reperfusion injury evolve, U 46619 will continue to underpin mechanistic and translational studies, with APExBIO providing validated, reliable supply to the scientific community. For further mechanistic insights, see this recent review, which situates U 46619 at the interface of platelet biology, GPCR signaling, and translational cardiovascular research.